Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Impressive Clinical Results For Argenx’s Oncology Candidate Seal The Deal for Janssen

Executive Summary

Janssen boosts its oncology pipeline with argenx’s novel anti-CD70 antibody, which has potential in a variety of indications.

Advertisement

Related Content

Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain
'Totality Of Data' Make A Case For Luspatercept In Beta-Thalassemia, MDS
More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay
First Approval Globally For Gilteritinib, In Japan For AML
Otsuka's Guadecitabine Fails in ASTRAL-1 But AML Studies Continue
Daiichi's Phase III Quizartinib Data Pave Way In Niche AML Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel